ALP Bio AG
to accelerate their platform which combines human immune organoid biology with generative AI to help antibody developers identify, understand, and reduce immunogenicity risk earlier in drug development.
Schlieren, Switzerlandalp.bio ↗
Total raised
€1.9M
€1,900,000
Funding rounds
1
Investors
3
distinct backers
Active since
2026-04
latest 2026-04
Funding by year
EUR raised per year · 2026 YTDSignals
High confidenceRaise-next likelihood15
base rate 24% for Pre-Seed
- ▼ Raised very recently
- ▼ Low backer re-investment
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-04-30 | Pre-Seed | €1.9M | 42CAP,strategic angel investors,Venture Kick | View deal → |
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Climeworks€920MSwitzerland · Cleantech
- Energy Vault€896MSwitzerland · Energy